Clinical Trial Update: A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) [Phase 2]

View source ↗

Summary

Phase 2 trial results for the combination of tepotinib and osimertinib in osimertinib-relapsed MET-amplified non-small cell lung cancer (INSIGHT 2) have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)
• Tepmetko (tepotinib)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-04